News
-
Dispensary Corner
Tuesday | Jun 19 2018
19 Jun 18WHY would a 73-year-old man choose to be entombed in a mini-shipping container with the road resealed above him?.
-
-
MedAdvisor doubles flu vax
Monday | Jun 18 2018MEDADVISOR pharmacies have recorded over 80,000 flu vaccinations via PlusOne so far this year, which when combined with available data from the Pharmacy Guild highlights a near doubling of vaccinations delivered in pharmacy in Apr and May this year.
-
MedAdvisor signs Zest
Monday | Jun 18 2018AUSTRALIAN-LISTED companies MedAdvisor and EBOS have inked a three year agreement linking EBOS subsidiary Zest with the medical management specialist.
-
FIP congress builds
Monday | Jun 18 2018THE International Pharmaceutical Federation (FIP) has said it has reached an all-time high for registrations and abstract submissions for its upcoming World Congress in Glasgow.
-
Technology update
Monday | Jun 18 2018THIS year's Pharmacy Connect conference will focus on rapidly growing and disruptive technology influencing the pharmacy business model in Australia.
-
License renewals due
Monday | Jun 18 2018PHARMACY, pharmacy department and pharmacy depot premises registration payments, and licences renewal payments to carry on a pharmacy business, are due to be received by the end of this month, the Victorian Pharmacy Authority (VPA) has reminded in its latest communiqu.
-
JAK inhibitor fear
Monday | Jun 18 2018AUSTRIAN researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas, according to a study published online in Blood, the Journal of the American Society of Hematology (ASH) - CLICK HERE.
-
EULAR likes MTX
Monday | Jun 18 2018THE major international European rheumatology conference, the European League Against Rheumatism (EULAR), has celebrated 30 years of use of one of its gold standard drugs, methotrexate (MTX), with researchers saying its "potential is far from exhausted".
-
Biosimilars stack up
Monday | Jun 18 2018NEW research lasting 54 weeks and sponsored by Novartis' generic and biosimilar arm Sandoz, has revealed that its biosimilars Zessly (infliximab) and Erelzi (etanercept) in rheumatoid arthritis have matched their respective reference drugs on a number of parameters.
